Korro Bio, Inc. (KRRO) - Total Liabilities
Based on the latest financial reports, Korro Bio, Inc. (KRRO) has total liabilities worth $63.99 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Korro Bio, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Korro Bio, Inc. - Total Liabilities Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check KRRO financial resilience to evaluate the company's liquid asset resilience ratio.
Korro Bio, Inc. Competitors by Total Liabilities
The table below lists competitors of Korro Bio, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ferronordic AB (publ)
ST:FNM
|
Sweden | Skr3.20 Billion |
|
Asia Plus Group Holdings PCL
BK:ASP
|
Thailand | ฿4.53 Billion |
|
Bank Windu Kentjana Int
JK:MCOR
|
Indonesia | Rp31.96 Trillion |
|
Fasadgruppen Group AB
ST:FG
|
Sweden | Skr4.36 Billion |
|
SOTKAMO SILVER AB NAM.
F:VSO
|
Germany | €359.70 Million |
|
Melnick Even Desenvolvimento Imobiliário S.A
SA:MELK3
|
Brazil | R$1.59 Billion |
|
Surya Toto Indonesia Tbk
JK:TOTO
|
Indonesia | Rp910.67 Billion |
|
Seoho Electric Co.Ltd
KQ:065710
|
Korea | ₩34.69 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Korro Bio, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Korro Bio, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Korro Bio, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Korro Bio, Inc. (2017–2025)
The table below shows the annual total liabilities of Korro Bio, Inc. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $62.07 Million | -5.71% |
| 2024-12-31 | $65.83 Million | +27.19% |
| 2023-12-31 | $51.75 Million | -70.05% |
| 2022-12-31 | $172.77 Million | +216.82% |
| 2021-12-31 | $54.53 Million | -24.50% |
| 2020-12-31 | $72.23 Million | +29.31% |
| 2019-12-31 | $55.86 Million | -37.28% |
| 2018-12-31 | $89.06 Million | +80.17% |
| 2017-12-31 | $49.43 Million | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more